{"id":"https://openalex.org/W2665075838","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.510","title":"MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.","display_name":"MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.","alternate_titles":[],"publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2665075838","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.510","mag":"2665075838"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.510","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.510","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.510","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2665075838"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069795948","display_name":"Maura N. Dickler","orcid":"https://orcid.org/0000-0003-4631-6572","observed_orcids":["https://orcid.org/0000-0003-4631-6572"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maura N. Dickler","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hope S. Rugo","raw_affiliation_strings":["University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051629490","display_name":"Javier Cort\u00e9s","orcid":"https://orcid.org/0000-0001-7623-1583","observed_orcids":["https://orcid.org/0000-0001-7623-1583"]},"institutions":[{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Javier Cortes","raw_affiliation_strings":["Vall d'Hebron Institute of Oncology, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d'Hebron Institute of Oncology, Barcelona, Spain;","institution_ids":["https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056565799","display_name":"Veronique C Dieras","orcid":"https://orcid.org/0000-0001-8094-4738","observed_orcids":["https://orcid.org/0000-0001-8094-4738","https://orcid.org/0000-0002-8798-6540"]},"institutions":[{"id":"https://openalex.org/I80043","display_name":"Institut Curie","ror":"https://ror.org/04t0gwh46","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I80043"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"V\u00e9ronique Di\u00e9ras","raw_affiliation_strings":["Institut Curie, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Curie, Paris, France;","institution_ids":["https://openalex.org/I80043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088119887","display_name":"Debra A. Patt","orcid":"https://orcid.org/0000-0001-5185-5170","observed_orcids":["https://orcid.org/0000-0001-5185-5170"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Debra A. Patt","raw_affiliation_strings":["Texas Oncology, Austin, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, Austin, TX;","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052697647","display_name":"Hans P. M. W. Wildiers","orcid":"https://orcid.org/0000-0001-8990-7837","observed_orcids":["https://orcid.org/0000-0001-8990-7837"]},"institutions":[{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hans Wildiers","raw_affiliation_strings":["University Hospitals Leuven and KU Leuven, Leuven, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals Leuven and KU Leuven, Leuven, Belgium;","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040919295","display_name":"Martin Frenzel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin Frenzel","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016796672","display_name":"Andrew G. Koustenis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrew Koustenis","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jose Baselga","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":71,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"510","last_page":"510"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8370000123977661},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.9089999794960022},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.8140000104904175},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8169999718666077},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9750000238418579},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.7639999985694885},{"id":"https://openalex.org/keywords/chemotherapy-refractory-disease","display_name":"chemotherapy-refractory disease","score":0.7350000143051147},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.414000004529953},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.6060000061988831},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.7369999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9305352568626404},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7026231288909912},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.698903501033783},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5516289472579956},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5304476618766785},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.49855518341064453},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48575976490974426},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4806881844997406},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4638998508453369},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.42899852991104126},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.41417834162712097},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3910243511199951},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34762537479400635},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2568296194076538}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.510","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.510","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.510","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2617437931","https://openalex.org/W2740335872","https://openalex.org/W2624659532","https://openalex.org/W2763363085","https://openalex.org/W2594780509","https://openalex.org/W3089214151","https://openalex.org/W2594795741","https://openalex.org/W2763742548","https://openalex.org/W2947876005","https://openalex.org/W2886380455"],"abstract_inverted_index":{"510":[0],"Background:":[1],"Abemaciclib":[2,107,305],"is":[3,48,110],"an":[4],"oral,":[5],"selective":[6],"inhibitor":[7],"of":[8,43,60,85,101,126,137,166,179,182,191,194,205,227,234,344],"CDK4":[9],"and":[10,58,76,90,148,153,214,258,280,335],"CDK6":[11],"dosed":[12],"on":[13,71,113,270],"a":[14,18,49,114,177,189,311],"continuous":[15,115],"schedule.":[16],"In":[17],"phase":[19,50],"1":[20,47,94],"trial,":[21],"abemaciclib":[22,61,173],"demonstrated":[23],"single-agent":[24],"activity":[25],"in":[26,63,103,313],"refractory":[27,316],"HR+":[28,317],"metastatic":[29,105,219],"breast":[30],"cancer":[31],"(MBC)":[32],"with":[33,65,146,172,315],"some":[34],"tumor":[35,308],"responses":[36,309],"occurring":[37],"after":[38,73,156],"8":[39,152,223,232,274],"or":[40,72],"more":[41,97],"mos":[42,155],"therapy.":[44,332],"Methods:":[45],"MONARCH":[46],"2":[51,99,192,218],"single-arm":[52],"study":[53],"designed":[54],"to":[55,132,299,331],"evaluate":[56,133],"safety":[57],"efficacy":[59,334],"monotherapy":[62,312],"women":[64],"HR+/HER2-":[66],"MBC":[67,319],"whose":[68],"disease":[69,121],"progressed":[70],"endocrine":[74],"therapy":[75,184],"chemotherapy.":[77],"Eligible":[78],"pts":[79,129,168,206,228,267,314],"had":[80,176,207,211,216,229,278,282],"measurable":[81],"disease,":[82,187,213],"ECOG":[83],"PS":[84,208],"0/1,":[86],"no":[87,96],"CNS":[88],"metastases,":[89],"received":[91,230],"at":[92,151,272,341],"least":[93],"but":[95],"than":[98],"lines":[100,181,193],"chemotherapy":[102,195],"the":[104,134,157,222,236,244,265,273,342],"setting.":[106],"(200":[108],"mg)":[109],"administered":[111],"orally":[112],"schedule":[116],"every":[117],"12":[118,154],"hours":[119],"until":[120],"progression.":[122],"A":[123,164],"sample":[124],"size":[125],"approximately":[127],"128":[128],"was":[130,201,242,256,261,325],"planned":[131],"primary":[135],"objective":[136,139,307],"investigator-assessed":[138],"response":[140],"rate":[141,247],"(ORR)":[142],"using":[143],"RECIST":[144,240],"v1.1,":[145],"interim":[147],"final":[149],"analyses":[150],"last":[158],"pt":[159],"started":[160],"treatment,":[161],"respectively.":[162],"Results:":[163],"total":[165],"132":[167],"have":[169],"been":[170],"treated":[171],"monotherapy.":[174],"Pts":[175],"median":[178,190,259],"3":[180],"prior":[183,322],"for":[185,196],"advanced":[186,197],"including":[188],"disease.":[198],"Median":[199],"age":[200],"58":[202],"(36-89),":[203],"44.7%":[204],"1,":[209],"90.2%":[210],"visceral":[212],"85.6%":[215],"\u2265":[217,231,253],"sites.":[220],"At":[221],"mo":[224,275],"interim,":[225,276],"35.6%":[226],"cycles":[233],"therapy;":[235],"confirmed":[237],"ORR":[238],"(per":[239],"v1.1)":[241],"17.4%,":[243],"clinical":[245],"benefit":[246],"(CR":[248],"+":[249,251],"PR":[250],"SD":[252],"6":[254],"mos)":[255],"42.4%,":[257],"PFS":[260],"5.7":[262],"mos.":[263],"Of":[264],"22":[266],"who":[268],"remained":[269],"treatment":[271],"13":[277],"responded":[279],"9":[281],"SD.":[283],"The":[284],"5":[285],"most":[286],"common":[287],"TEAEs":[288],"were":[289,301],"diarrhea,":[290],"fatigue,":[291],"nausea,":[292],"decreased":[293],"appetite,":[294],"abdominal":[295],"pain;":[296],"discontinuations":[297],"due":[298],"AEs":[300],"infrequent":[302],"(6.8%).":[303],"Conclusions:":[304],"induces":[306],"as":[310],"HER2-":[318],"following":[320],"multiple":[321],"therapies.":[323],"Treatment":[324],"well":[326],"tolerated,":[327],"allowing":[328],"prolonged":[329],"exposure":[330],"Updated":[333],"tolerability":[336],"data":[337],"will":[338],"be":[339],"provided":[340],"time":[343],"presentation.":[345],"Clinical":[346],"trial":[347],"information:":[348],"NCT02102490.":[349]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2665075838","counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":36},{"year":2016,"cited_by_count":12}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2017-06-30T00:00:00"}
